|Assessment Status||Rapid review complete|
|Drug||Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|
|Indication||For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir|
|Rapid review commissioned||06/12/2018|
|Rapid review completed||16/01/2019|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Destrigo® be considered for reimbursement.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement; February 2019